Associate Professor, Pathology-Brigham and Women's Hospital, Harvard Medical School
Pathology
Dr. Scott J. Rodig, MD
|
|
Give Review
Scott Rodig practices Pathology. He went to Washington University School of Medicine in St. Louis. Scott Rodig is also published. He has 104 publications published. The lastest publication: "Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice.
- Immunological mechanisms of the antitumor effects of supplemental oxygenation.
- Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations.
- Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens.
- A Zebrafish Model of Myelodysplastic Syndrome Produced Through tet2 Genomic Editing.
- Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.
- Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection.
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma.
- Myc Protein Expression Correlates With MYC Amplification In Small Cell Lung Carcinoma.
- Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell Acute lymphoblastic leukaemia.
- The importance of central pathology review in international trials: a comparison of local vs. central bone marrow reticulin grading.
- The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macrogl...
- Outcomes in patients with relapsed or refractory multiple Myeloma in a phase I study of everolimus in combination with lenalidomide.
- Comparison of referring and final pathology for patients with T-cell Lymphoma in the National Comprehensive Cancer Network.
- MYC Protein Expression Is Detected in Plasma Cell Myeloma but Not in Monoclonal Gammopathy of Undetermined Significance (MGUS).
- High concordance in grading reticulin fibrosis and cellularity in patients with Myeloproliferative neoplasms.
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma.
- NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth.
- Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell Lymphoma.
- Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell Lymphomas: A North American PTCL Study Group Project.
- Mantle Cell Lymphoma in Cyclin D1 Transgenic Mice with Bim-deficient B-cells.
- Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell Lymphoma.
- A targeted mutational landscape of angioimmunoblastic T cell Lymphoma.
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors.
- Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin Lymphoma.
- Microbial colonization influences early B-lineage development in the gut lamina propria.
- Improving the quality of bone marrow assessment: Impact of operator techniques and use of a specimen preparation checklist.
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies.
- Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer.
- Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.
- Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell Lymphoma.
- KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell Acute lymphoblastic leukaemia and Acute ...
- Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell Lymphomas.
- Sphingosine-1-phosphate receptor 1 in classical Hodgkin Lymphoma: assessment of expression and role in cell migration.
- Low frequency clonal mutations recoverable by deep sequencing in Patients with aplastic Anemia.
- Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells.
- Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo.
- Results of the phase II trial of single agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia.
- A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
- Next-generation cDNA screening for oncogene and resistance phenotypes.
- The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers.
- Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma.
- MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
- Autocrine activation of the MET receptor tyrosine kinase in Acute myeloid leukemia.
- Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis.
- Preserved function of regulatory T cells in Chronic HIV-1 infection despite decreased numbers in blood and tissue.
- Expression of Interleukin-4 Receptor Alpha by Human Pleura Mesothelioma is Associated with Poor Survival and Promotion of Tumor Inflammation.
- Molecular ontogeny of donor-derived follicular Lymphomas occurring after hematopoietic cell transplantation.
- Detection of IDH1 R132H mutation in Acute myeloid leukemia by mutation-specific immunohistochemistry.
- Emerging Targeted Therapies for Lymphoid Malignancies.
- Defining the role of TORC1 and TORC2 in multiple Myeloma.
- Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These T...
- Significant biological role of Sp1 transactivation in multiple Myeloma.
- Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
- A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
- MSI2 protein expression predicts unfavorable outcome in Acute myeloid leukemia.
- The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.
- Epithelial adhesion molecules can inhibit HIV-1-specific CD8? T-cell functions.
- Circulating and tumor-infiltrating Myeloid cells predict survival in human pleural mesothelioma.
- Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative Disorders.
- Sunitinib inhibits postoperative adhesions in a rabbit model.
- Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program.
- Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells.
- Hepcidin is produced by lymphoplasmacytic cells and is associated with Anemia in Waldenström's macroglobulinemia.
- Optical techniques for tracking multiple Myeloma engraftment, growth, and response to therapy.
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
- The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
- Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
- TIM-3: a novel regulatory molecule of alloimmune activation.
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin Lymphoma an...
- A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice.
- Altered subcellular localization of c-Myc protein identifies aggressive B-cell Lymphomas harboring a c-MYC translocation.
- Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.
- MLL-rearranged B lymphoblastic Leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
- Plasma organochlorine levels and risk of non-Hodgkin Lymphoma in a cohort of men.
- A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.
- Functional screening identifies CRLF2 in precursor B-cell Acute lymphoblastic leukemia.
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
- Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
- Essential role for TRPC5 in amygdala function and fear-related behavior.
- Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.
- Lipocalin 2 promotes breast cancer progression.
- The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response.
- Genomic instability resulting from Blm deficiency compromises development, maintenance, and function of the B cell lineage.
- Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.
- AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell Lymphomas from other lymphoid malignancies with shared molecular features.
- Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.
- Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive Lymphomas harboring a MYC translocation.
- The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin Lymphoma.
- Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell Lymphoma from other types of diffuse large B-cell Lymphoma.
- Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
- Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative Disorders.
- BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative Disorders.
- TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin Lymphoma from a subset of morphologically or immunophenotypically similar...
- The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative Disorders.
- CCR6 is a functional chemokine receptor that serves to identify select B-cell non-Hodgkin's Lymphomas.
- Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.
- MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice.
- Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high ...
Schools
Washington Center School of Medicine
Brigham and Women39s Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Leukocytosis
- View All
Doctors Specialties
- Hematology
- Hematopathology
- Pathology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1154388239 | |
| NPPES Provider LastName | RODIG | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Pathology | |
| Total Claim Count | 43.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1154388239 |
| Last Name Of The Provider | RODIG |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. Rushdia Z. Yusuf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth L. Fingar, MD |
|
|
Dr. Mark S. Stonecypher, MD |
|
|
Dr. Samuel Y. Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandro Santagata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaleh Mansouri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Justine M. Carr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kira Gritsman, MD |
|
|
Dr. Mona S. Kaddis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bita Tabesh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alfred I. Tauber, MD
This Doctor is OpenDoctor Recommended.
|